The Journal of Pharmaceutical Investigation, a peer-reviewed publication covering pharmaceutical sciences and drug development research, has been confirmed as abstracted and indexed in Science Citation Index Expanded, also known as SciSearch, since 2021. According to the latest bibliometric data, the journal now carries an Impact Factor of 5.5 for 2022, placing it in the first quartile of its field with a rank of 48 out of 278 journals in the Pharmacology and Pharmacy category. The announcement, published through the journal’s listing with Springer, marks a significant milestone for a title that has been steadily building its international visibility among researchers working on drug delivery, formulation science, and pharmaceutical technology.
Abstracting and indexing is the process by which a journal’s published articles are systematically catalogued in major bibliographic databases, allowing them to be discovered, cited, and tracked by the global research community. Inclusion in the Science Citation Index Expanded, one of the core citation databases maintained within the Web of Science platform, signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial board composition, peer-review integrity, international diversity of authorship, and the consistency of its scholarly output. For pharmaceutical researchers, this means that articles appearing in the journal are now fully searchable alongside the most influential literature in pharmacology and pharmacy, and that citations to those articles are counted in official journal metrics.
The Impact Factor, the most widely recognized of these metrics, is calculated by dividing the number of citations received in a given year by articles published in the two preceding years. A value of 5.5 for 2022 indicates that, on average, papers published in the journal during 2020 and 2021 were cited 5.5 times in 2022. This figure places the journal comfortably within the upper tier of its category, since quartile rankings divide the journals in a subject class into four equal groups by citation performance. A Q1 designation, corresponding to the top 25 percent of the 278 journals ranked in Pharmacology and Pharmacy, is a benchmark many institutions use when assessing publication quality for hiring, promotion, and funding decisions.
The rank of 48 out of 278 is particularly notable in a category as large and competitive as Pharmacology and Pharmacy, which spans everything from basic molecular pharmacology to clinical therapeutics and pharmaceutical manufacturing. Journals in this category compete for citations from a vast body of global research, and moving into the first quartile typically requires sustained growth in both the quality and the visibility of published work. For a journal focused specifically on pharmaceutical investigation, the achievement reflects the growing citation footprint of research on drug delivery systems, nanomedicine, pharmacokinetics, and the formulation technologies that translate laboratory discoveries into clinical products.
Indexing in SciSearch since 2021 means the journal’s metrics are still relatively young within the Web of Science ecosystem, which makes the 2022 Impact Factor an early but meaningful indicator of its trajectory. New journals often take several years to accumulate the citation history needed for stable rankings, and early Impact Factors can fluctuate as the indexed back-file grows. A first-quartile placement within roughly two years of indexing suggests that the journal’s existing body of work was already attracting substantial citations, and that its inclusion in the database made that influence visible to the evaluators, librarians, and researchers who rely on these metrics to navigate the literature.
The practical consequences of indexing and quartile performance extend well beyond prestige. Researchers choosing where to submit manuscripts frequently consult journal rankings to maximize the reach and career value of their work, and many funding agencies and universities maintain lists of approved outlets based on Web of Science categories and quartiles. Librarians use the same data to make subscription decisions. For authors in pharmaceutical sciences, a Q1 journal with a 5.5 Impact Factor offers a combination of disciplinary focus and broad discoverability that can accelerate the uptake of new methods, from controlled-release formulations to novel excipients and biopharmaceutical characterization techniques.
Bibliometric experts caution, however, that the Impact Factor is a blunt instrument. It measures average citations to a two-year window of articles and can be influenced by a small number of highly cited reviews, by the overall volume of publication, and by citation practices that vary across subfields. Pharmacology and pharmacy journals, which sit at the interface of basic science and applied medicine, often benefit from citation patterns that differ from those of purely clinical or purely basic titles. For this reason, evaluators are increasingly encouraged to read quartile rankings alongside other indicators, such as the journal’s scope, its peer-review standards, and the actual readership of individual papers rather than journal-level averages alone.
Even with those caveats, the formal recognition matters for the research community the journal serves. Pharmaceutical investigation is a field in which translational timelines are long and the path from molecular discovery to approved therapy depends on shared methodological standards. When a specialized journal achieves first-quartile status, it strengthens the visibility of the applied and formulation-oriented research that often falls between the traditional categories of pharmacology and chemical engineering. This can help ensure that advances in drug delivery technology, bioequivalence assessment, and pharmaceutical quality control receive the same citation attention as breakthroughs in target discovery or clinical trial results.
The journal’s listing with Springer, which publishes the title as part of its pharmaceutical sciences portfolio, provides the authoritative record of its indexing status and metric performance. The publisher’s announcement confirms both the 2021 start of Science Citation Index Expanded coverage and the 2022 Impact Factor of 5.5, along with the category rank of 48 out of 278 in Pharmacology and Pharmacy. These figures will be updated annually as new citation data become available, and the journal’s position will be watched by authors, editors, and bibliometric analysts alike as an indicator of how specialized pharmaceutical research titles fare in an increasingly metrics-driven publishing environment.
For the broader scientific publishing landscape, the case illustrates how abstracting and indexing functions as the gateway through which journals enter the formal economy of scholarly recognition. Without inclusion in the major citation databases, even high-quality research risks invisibility in the evaluations that shape careers and funding. With inclusion, and with a strong early Impact Factor, a journal can rapidly become a destination for the work that defines its field. The Journal of Pharmaceutical Investigation’s Q1 standing demonstrates that a focused pharmaceutical title can achieve that recognition quickly, provided its published research resonates with the citation behavior of the international pharmacology and pharmacy community.
Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with a Q1 rank of 48/278 in Pharmacology and Pharmacy
Article Title: Abstracting and Indexing
Article References: Abstracting and Indexing. (n.d.). Original publication
Image Credits: AI Generated
DOI: Not provided
Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, quartile ranking, pharmacology and pharmacy, Web of Science, bibliometrics, pharmaceutical sciences, Springer, citation metrics
Cite Scienmag News
APA MLA Chicago
Louis Brooks. (September 20, 2026). Journal of Pharmaceutical Investigation Earns Q1 Ranking With 5.5 Impact Factor. Scienmag. https://scienmag.com/journal-of-pharmaceutical-investigation-earns-q1-ranking-with-5-5-impact-factor-3/
Louis Brooks. “Journal of Pharmaceutical Investigation Earns Q1 Ranking With 5.5 Impact Factor.” Scienmag, 20 September 2026, https://scienmag.com/journal-of-pharmaceutical-investigation-earns-q1-ranking-with-5-5-impact-factor-3/. Accessed 20 September 2026.
Louis Brooks. “Journal of Pharmaceutical Investigation Earns Q1 Ranking With 5.5 Impact Factor.” Scienmag. September 20, 2026. https://scienmag.com/journal-of-pharmaceutical-investigation-earns-q1-ranking-with-5-5-impact-factor-3/
Copy citation Download RIS
Tags: abstracting and indexingbibliometric analysis of pharmaceutical journalsbibliometricscitation metricsdrug delivery and formulation sciencedrug development research journalfirst quartile pharmacology journalsImpact Factorindexing and abstracting in scientific databasesinternational visibility of pharmaceutical researchJournal of Pharmaceutical Investigationpeer-reviewed pharmaceutical research publicationpharmaceutical investigation journal impact factorpharmaceutical sciencespharmaceutical technology publication standardsPharmacology and Pharmacyquartile rankingresearch dissemination in pharmaceutical sciencesscholarly publishing in pharmacologyScience Citation Index ExpandedScience Citation Index Expanded inclusionSciSearchSpringerWeb of Science
